Drug News

Global Biomarker Collaboration and Licensing Partnering Analysis Report 2016-2023

The “Biomarker Collaboration and Licensing Deals 2016-2023” report, now available on ResearchAndMarkets, offers a comprehensive and up-to-date overview of biomarker deals within the biopharmaceutical industry. This valuable resource encompasses 463 biomarker deals announced since 2016, presenting financial terms where available and providing links to online deal records disclosed by the involved parties.

The report delves into the intricate landscape of biomarker deals, offering insights into collaborative research and development initiatives, as well as the commercialization of outcomes. The scope of the report spans collaboration, development, research, and licensing deals within the biomarker domain. Furthermore, it includes contract documents submitted to the Securities Exchange Commission by companies and their partners when available, adding an additional layer of depth to the analysis.

Key Features:

1.        Comprehensive Deal Listings (2016-2023): The report provides a detailed understanding of biomarker deals announced between 2016 and 2023, offering readers unprecedented access to the intricacies of these agreements.

2.        Multicomponent Deals Analysis: Biomarker deals are often complex and involve multiple components. The report analyzes the various dimensions of these deals, starting from collaborative R&D efforts and extending to the commercialization of the outcomes.

3.        Financial Terms Overview: Financial terms, including upfront payments, milestones, and royalties, are outlined, providing readers with a benchmark for assessing the market value of transactions.

4.        Contract Documents Access: The inclusion of contract documents submitted to the Securities Exchange Commission by companies and their partners allows readers to access detailed insights into deal structures, facilitating in-depth due diligence.

5.        Deal Trends and Activities: The report includes numerous tables and figures illustrating the trends and activities in biomarker deal-making since 2016. This aids in identifying patterns and shifts in the landscape over time.

6.        Deal Directory: A comprehensive deal directory is organized by company A-Z, deal type, and therapeutic target, offering readers a quick and organized way to navigate and understand the biomarker deals landscape.

Chapter Highlights:

•          Introduction: Chapter 1 introduces the report, setting the stage for the subsequent chapters.

•          Deal Trends Overview: Chapter 2 provides an overview of the trends in biomarker deal-making since 2016, offering context for readers to understand the evolution of these agreements.

•          Top Deals: Chapter 3 outlines the leading biomarker deals since 2016, listing them by headline value, and providing a snapshot of significant transactions within the industry.

•          Company Analysis: Chapter 4 identifies the top 25 most active companies in biomarker deal-making, offering a brief summary followed by a comprehensive listing of biomarker deals, including publicly available contract documents.

•          Detailed Review of Deals: Chapters 5 and 6 provide a comprehensive and detailed review of biomarker deals signed and announced since January 2016. This includes an overview of deals where contract documents are available and a focused analysis of biomarker partnering deals organized by specific technology types.

Key Benefits for Readers

•          Deal Trends Understanding: Gain insights into biomarker deal trends since 2016, enabling a nuanced understanding of the evolving landscape.

•          Benchmark Analysis: Identify the market value of transactions, including upfront payments, milestones, and royalties, allowing for benchmarking against industry standards.

•          Directory Access: Easily navigate the biomarker deals landscape with a directory organized by company, deal type, and therapy area.

•          Deal Structuring Insights: Access contract documents to gain valuable insights into deal structures, aiding in due diligence and assessing the suitability of proposed deal terms.

•          Time Efficiency: Save significant research time with a consolidated and comprehensive resource covering biomarker collaboration and licensing deals.

In conclusion, the “Biomarker Collaboration and Licensing Deals 2016-2023” report serves as an invaluable tool for industry professionals, researchers, and decision-makers seeking a deep and current understanding of the biomarker landscape, deal trends, and key players in the biopharmaceutical sector.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker